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The research undertaken for this MPH dissertation examines the effect of distance on the 
maintenance of INR therapeutic ranges in rheumatic heart disease patients in Cape Town. 
 
Part A is the research protocol which outlines the background and the process of this 
research.  This study is a population-based observational study nested within the Groote 
Schuur Hospital (GSH) cohort of a global study, REMEDY which is a prospective, 
multicentre, hospital-based registry for rheumatic heart disease (RHD). This study made use 
of geographical information systems (GIS) as a tool to investigate the effect of distance on 
the maintenance of INR therapeutic ranges in RHD patients.   
 
Part B elaborates on the background and highlights the importance of this research by 
exploring the existing theoretical and empirical literature relevant to the topic. It describes the 
importance of the maintenance of the INR therapeutic range and how geographical factors 
can influence patient adherence to medication, and how it can act as a barrier to access 
health care.  It provides examples of how GIS has been used to investigate the effect of 
distance on adherence in other studies.  This literature review aimed to establish whether 
the maintenance of therapeutic ranges in RHD patients on anticoagulant therapy is 
correlated with the distance travelled from patient’s residence to the clinic where INR 
monitoring takes place. 
 
Part C presents the entire research project in a format suitable for journal submission. The 
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PROTOCOL SUMMARY 
 
Title:  The effect of distance to health facility on the maintenance of INR 
therapeutic ranges in rheumatic heart disease patients from Cape Town 
Rheumatic heart disease (RHD) patients who have had valvular replacements 
or have been diagnosed with atrial fibrillation (AF) require anticoagulation 
therapy.  Therapeutic anticoagulation is measured by the international 
normalised ratio (INR) on a monthly basis once therapeutic levels in individual 
patients have stabilised. Lack of concordance with monthly INR monitoring in 
RHD patients is considered to be a contributor to stroke and other 
complications.  Various factors for non-concordance have been suggested 
including limited access to health care facilities.   
We hypothesize that the maintenance of INR therapeutic ranges in RHD 
patients is correlated with the travel distance from the patient’s residence to the 
health care facility to which they have been referred.  The aim of this study is to 
utilize Geographical Information Systems (GIS), which enables the visual 
representation of data so as to establish patterns and trends, to develop a 
spatial display instrument, mapping the residential addresses of patients against 
their respective designated referral clinic, so as to investigate the effect of 
distance  on the maintenance of INR therapeutic ranges in rheumatic heart 
disease patients.  
Design: Population-based, Observational. 
Population: Hospital patients with echocardiography-
confirmed RHD enrolled in the REMEDY 
study. 
Sites: The Cape Town Metropole, South Africa 
Study Duration: Duration of data collection & analysis: 3 
months 
Instrument & Methods:      This thesis will use existing (12 month follow-
up) data nested within Remedy, a register-
based system for capturing RHD data 
amongst consenting Groote Schuur Hospital 
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In patients on anticoagulation therapy:  
 To correlate the distance of RHD patients’ residences from their 
designated referral clinic with the maintenance of INR levels  
 
Secondary:  
 To determine the distance from RHD patients’ residence to the closest 
clinic 
 To map the pattern of clinic utilization amongst RHD patients through 
the development of spatial display images 
 To report the average INR levels among RHD patients  
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Definition of Terms 
ARF Acute Rheumatic Fever 
RHD Rheumatic Heart Disease 
GAS Group A Streptococcus 
GIS Geographical Information System 
CRF Case Report Form 
INR International Normalized Ratio 
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1. BACKGROUND TO THE RESEARCH  
 
Rheumatic heart disease (RHD), a condition characterised by permanent 
damage to the heart valves, is a consequence of repeated episodes of acute 
rheumatic fever in patients with failed secondary prophylaxis (Nkomo, 2007).  
The developed world has experienced a decline in the prevalence of RHD 
through improved living conditions and the use of penicillin for the treatment of 
Group A streptococcal pharyngitis.  On the other hand, developing countries 
which account for 80% of the world’s population continue to experience high 
cases of RHD;  RHD and its precursor, acute rheumatic fever (ARF) are the 
most common diseases affecting children and young adults in the world 
(Carapetis et al., 2005).   
Primary and secondary prevention strategies to prevent disease progression, 
have been implemented in many parts of the world as per the World Health 
Organisation recommendations (WHO, 2004).   Primary prevention specifically 
targets the correct management of GAS pharyngitis with penicillin, to avoid the 
later development of ARF (Robertson et al., 2005).  If the first episode of ARF is 
not prevented, further episodes of ARF are prevented through the 
administration of a monthly prophylactic penicillin injection,  known as 
secondary prevention (Manyemba and Mayosi, 2003).  Worsening of valvular 
lesions in RHD patients can also be prevented through secondary prevention. .  
 Once damage to the valves have occurred, expensive heart valve surgery may 
be necessary failing which, the condition is usually fatal.  Valvular repair or 
replacement with mechanical or biological prosthetic valves carries the risk of 
blood clot formation and embolism which may result in stroke (Salem et al. 
2006).  To prevent this complication, anticoagulant drugs such as warfarin are 
prescribed (Salem et al. 2006).  Warfarin interferes with the vitamin K 
availability, thus prolonging the normal prothrombin time (PT) and preventing 
excess clotting (Hirsh et al. 2013).  Anticoagulant levels in patients are 
monitored using the so-called International Normalized Ratio (INR).  INR 
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individuals and is represented as a ratio. Therapeutic levels representing 
normal values are between 2.00 – 3.00 for patients without valve replacements 
and 2.5 – 3.5 for patients with mechanical prosthetic valve replacements (Hirsh 
et al. 2013).  Too high an INR value indicates a risk for abnormal bleeding, 
while too low a value indicates that the patient is not protected against clot 
formation.  It is thus important to monitor patients’ INR values on a regular basis
so as to ensure that anticoagulant levels are maintained within the 
recommended ranges so as to ensure that therapies are effective in their 
function to reduce the risk of stroke and other complications in RHD patients.     
2. Rationalé
The safety and effectiveness of anticoagulant therapy is crucially dependant on
maintaining the INR within the therapeutic range (Hirsh et al. 2003). 
Anticoagulant treatment requires regular laboratory-guided adjustments of the
dose as response to treatment is affected by interactions with food and drugs
(Wallentin et al. 2010). Anticoagulation therapy with warfarin is highly effective
at reducing the risk of stroke, but is associated with monitoring costs and a 
higher risk of haemorrhage compared with other treatments (Mant et al. 2007). 
The lack of concordance to monthly INR monitoring can thus cause
complications such as stroke in RHD patients. Various factors for non-
concordance have been suggested including limited access to health care
facilities (figure 1).   
Geographical factors such as distance from the patients’ residence to their
health care facility, so-called “Distance Decay”,  were shown to be a significant
barrier to access (Gabrysch & Campbell 2009).  It has also been shown that the 
usage of health services decreases as the distance to the patients’ residence 
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The aim of this research is to evaluate distance as a factor in monitoring INR 
levels in RHD patients within the REMEDY cohort.   Specifically, this study aims 
to investigate whether the distance of a patient’s residence from their referral or 
treatment clinic impacts on maintaining INR levels within the recommended 
therapeutic ranges over the scheduled monthly visits to the clinic. To date, the 
effect of distance decay on INR monitoring in patients’ with RHD, has not been 
evaluated.  
This work will develop a spatial display instrument for RHD cases to enable the 
mapping of patients’ residential addresses and the referral clinic where they 
receive their monthly INR reading. Our results will inform healthcare providers 
where best to refer patients requiring monthly visits to clinics for INR monitoring.  
Furthermore, this work will inform the distribution of resources and personnel, 
Figure 1: WHO's multidimensional adherence model 
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specifically taking into account patients’ place of residence and areas where 
follow-up and concordance are lacking.  Finally, it will also serve to highlight 
target clinics for awareness-raising interventions amongst patients, communities 
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3. Objectives 
 
3.1 Hypothesis:    
INR measurement control is correlated with the distance from patients’ 
residence to the community clinic to which they have been referred for 
anticoagulation therapy.  We hypothesis that the rate of failure to maintain the 
INR therapeutic range increases as the distance between patients’ residence 
and treatment clinic increases,  
3.2 Primary objective:  
In patients on anticoagulation therapy:  
 To correlate the distance of RHD patients’ residences from their 
designated referral clinic with the maintenance of INR levels  
 
3.3 Secondary objective:  
 To evaluate the distance from RHD patients’ residences to the closest 
clinic 
 To map the pattern of clinic utilization amongst RHD patients through the 
development of spatial display images 
 To report the average INR levels among RHD patients  
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4. METHODS 
4.1 Study Design 
 
This study is a population-based observational sub-study nested within the 
Groote Schuur cohort of a global RHD study, REMEDY which is a prospective, 
multicentre, hospital-based registry (Karthikeyan et al., 2011). The Remedy 
project aims to provide comprehensive, contemporary data on patients with 
RHD and will help in the development of strategies to prevent and manage RHD 
and its complications.   
 
4.2 Recruitment and enrolment 
 
4.2.1 Population 
Patients diagnosed with RHD and enrolled at Groote Schuur Hospital into the 
REMEDY study. 
Inclusion / exclusion criteria 
All patients recruited at the Cape Town REMEDY site for whom complete data 
are available  for 12 month follow up and who reside in the Cape Metropole 
area.  
4.2.2 Method of sampling 
The sample will comprise a convenience sample of all the patients within the 




This study will utilize Geographical Information Systems, better known by its 
acronym GIS, for capturing, manipulating, managing, analysing and displaying 
spatial and non-spatial data.  The software has the ability to display various 
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system (Evans, 1997). In essence, GIS overlaps layers of information within a 
geographical area to give a better understanding from a composite viewpoint.  
The data in GIS is stored with geographical identifiers to enable for the data to 
be spatially located in the form of a map.  Maps allow data sets to be viewed, 
understood, visualised and interpreted in many ways that reveal trends, 
patterns and relationships that could not be seen in two-dimensional tables or 
lists.  GIS has been applied in a number of disciplines including civil 
engineering, geography and medical sciences. 
 
4.3.1 Data collection instruments and processes 
 
Patient data such as the diagnosis of ARF and RHD, residential addresses, 
assigned referral clinics and the latest three INR readings will be obtained from 
REMEDY patient records and captured into a purpose-designed database.  In 
addition, government clinics across the metropole will be mapped using 
information supplied by the Department of Surveying and Mapping in Mowbray, 
Cape Town.  All addresses will be converted to geographical coordinates and 
coordinates will be obtained from Google Earth®.  The Geocoded addresses will 
be further checked in ArcGIS for errors in coordinate data.  ArcGIS 10® software 
will be used for mapping and spatial analyses.  The travel distance between 
individual residential addresses and referral clinics will be calculated and 
compared with the average of the latest three INR measurement readings of the 
patient.  Additional outcomes include mapping the clinics to which patients are 
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Step 1: 
The researcher will retrieve, from the patients’ case report form (a collection 
instrument for demographic and diagnostic information) of the Remedy 
database, the following: 
 physical residential address
 Clinic for referral
 Diagnosis
 Latest 3 INR measurement readings
Figure 2 below is an excerpt from the Case Report Form and the information
that would be obtained from it.
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Step 2: 
Google Earth®, a virtual globe, map and geographical information programme, 
will be used to establish the longitude and latitude coordinates for the physical 
address of the patients. Patients’ residence on the street map provided is 
returned in decimal degrees. 
Figure 3 below demonstrates how Google Earth will be used to establish 
coordinates for the various addresses of RHD patients.  
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Step 3: 
 
Google Maps® will be used to establish the closest road travel distance 
between the patients’ residences and their treatment INR clinic using the 
coordinates obtained in step 2.  
Figure 4 below displays how Google Maps will be used determine the shortest 
road travel distance between patients’ residence and their treatment clinic. 
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Step 4: 
The data retrieved will be captured into a Microsoft Excel spreadsheet, together 
with the co-ordinates obtained from Google Earth.  The coordinates are given in 
“decimal degrees” for input into the ArcGIS software.  
Once the co-ordinates are presented in this format, the data are converted into 
a comma-delimited (CSV) file. 
Refer to Figure 5 demonstrating the data in the spreadsheet together with the 
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Step 5: 
ArcGIS version 10 ® will be used to map and spatially analyse the data. The 
Comma-delimited CSV file will be imported into ArcMAP where the visual 
representation of the data will be displayed in the form of a ‘picture’.  Figure 6 is 
an illustration of the output which will eventually map the patients’ residence as 
well as their referral clinic. 
 
 
Figure 6: ArcMAP - Spatial representation of patients and clinics in the Cape Metropole 
 
4.3.2 Validity and reliability of measuring instruments. 
 
While epidemiologists have traditionally used maps when analyzing 
associations between location, environment, and disease (Gesler, 1986), the 
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and new component in many epidemiological and health projects (Cromley, 
2003).  GIS technology aids the epidemiologist in understanding the subject 
under investigation to initiate interventions promptly.  GIS presents statistical 
data in a spatially referenced manner through maps.    
 
In particular, GIS enables the epidemiologist to: 
 Determine geographic distributions of disease 
 Observe surveillance and control infectious diseases 
 Determine epidemics, monitor the growth and assists in the best 
approach with regard to intervention strategies 
 Analyse spatial and temporal trends of disease, and 
 Determine the population at risk by creating risk maps using the buffer 
tool in GIS. 
 
GIS is particularly well suited for studying these associations because of its 
spatial analysis and display capabilities.   
In a recent study conducted in Vietnam, GIS was used to investigate the effect 
of distance decay on delivery care utilisation (Målqvist et al. 2010). Distance 
decay is a term given to describe different settings and patient groups (Müller et 
al. 1998).  The study examined the association between distance from a 
mothers’ home to the closest health care facility as well as neonatal mortality. It 
then investigated the influence of distance on patterns of perinatal health care 
utilisation. The study found an increased risk of neonatal mortality among 
mothers living farthest away from a health facility.  
In another study conducted in Baltimore County, Maryland, GIS and 
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factors associated with Lyme disease outbreak (Glass et al., 1995).  Ecologic 
data such as watershed, land use, soil type, geology, and forest distribution 
were collected at the residences of Lyme disease patients and compared with 
data collected at a randomly selected set of addresses of unaffected individuals 
acting as controls.  Data collected were layered within a GIS framework, 
generating spatial maps for a visual understanding of the extent of the 
epidemic.  Finally, a risk model was generated combining both GIS and logistic 
regression analysis to locate areas where Lyme disease is most likely to occur.   
In another study, also conducted in the USA, GIS was used in designing a
national surveillance system for monitoring animal rabies cases. The system
included data on positive and negative rabies cases as well as environmental
information such as land use. The system provided a ne resource for the
rapid mapping and dissemination of data on animal rabies cases in relation to
unaffected areas (Blanton et al. 2006) (Blanton et al., 2006). 
GIS presents as an ideal tool with which to evaluate the effect of distance on
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5. DATA ANALYSIS 
 
The data collected from the Remedy database for the purpose of this study as 
previously outlined, will be tabulated in an excel spreadsheet and analysed 
using STATA® version 11 and ArcGIS® version 10.  The results will be stratified 
in terms of patients with and without valve replacements as their therapeutic 




The researcher will commence with the research project June 2013 and is 
anticipated to last 3 months.    
 
 June July August 
Patient data extraction    
Data collation    
Analysis     
Write-up and compilation of final report    
 
This time period would allow the researcher to establish coordinates for all the 
patients in the Remedy database, investigate their concordance patterns to 
follow-up visits where they receive their monthly INR measurement readings 
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7. ETHICS 
 
This research thesis project is part of a larger research project that has already 
been approved by the HREC at UCT (028/2006).  Specifically, this work will 
contribute to the analysis component of the registry, utilizing secondary data 
and will not involve any physical interaction with participants. Furthermore, there 
will be no direct benefits to the participants as a result of this study. All patient 
data used for the purpose of this research will be treated as confidential and 




This research forms part of the dissertation for the Master of Public Health 
degree at the University of Cape Town. A copy of this dissertation will be made 
available at the Health Sciences library. 
A manuscript describing the project and the results will be prepared according 
to the guidelines of a specific and appropriate peer reviewed journal and will be 
submitted for publication.   
A scientific paper will also be prepared with the intent of an oral presentation at 













P a g e  | 22 
Part A: Research Protocol  
9. REFERENCES 
 
BLANTON, J.D. ET AL., 2006. Development of a GIS-based , real-time Internet 
mapping tool for rabies surveillance. International Journal of Health Geographics, 
5(47), pp.1-8. 
CARAPETIS, J.R., McDonald, M. & Wilson, N.J., 2005. Acute rheumatic fever. Lancet, 
366(9480), pp.155–68. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16005340. 
CROMLEY, E. K. 2003. GIS and disease. Annu Rev Public Health, 24, 7-24. 
EVANS, J. 1997. The lay of the land: GIS and mapping software. Health Manag 
Technol, 18, 58, 60. 
GABRYSCH, S. & CAMPBELL, O.M.R., 2009. Still too far to walk: literature review of 
the determinants of delivery service use. BMC pregnancy and childbirth, 9, p.34. 
GESLER, W. 1986. The uses of spatial analysis in medical geography: a review. Soc 
Sci Med, 23, 963-73. 
GLASS, G. E., SCHWARTZ, B. S., MORGAN, J. M., 3RD, JOHNSON, D. T., NOY, P. 
M. & ISRAEL, E. 1995. Environmental risk factors for Lyme disease identified with 
geographic information systems. Am J Public Health, 85, 944-8. 
HIRSH, J. et al., 2003. American Heart Association/American College of Cardiology 
Foundation guide to warfarin therapy. Circulation, 107(12), pp.1692–711. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12668507 [Accessed May 22, 2013]. 
KARTHIKEYAN, G., ZÜHLKE, L., ENGEL, M. E. & AL., E. 2011. Rationalé and Design 
of A Global Rheumatic Heart Disease Registry: The REMEDY Study. American Heart 
Journal, Submitted. 
MÅLQVIST, M. et al., 2010. Distance decay in delivery care utilisation associated with 
neonatal mortality. A case referent study in northern Vietnam. BMC public health, 
10(1), p.762. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3009650&tool=pmcentrez&r
endertype=abstract [Accessed March 19, 2013]. 
MANT, J. et al., 2007. Warfarin versus aspirin for stroke prevention in an elderly 
community population with atrial fi brillation ( the Birmingham Atrial Fibrillation 
Treatment of the Aged Study , BAFTA ): a randomised controlled trial. Lancet, 370, 
pp.493–503. 
MANYEMBA, J. & MAYOSI, B. M. 2003. Intramuscular penicillin is more effective than 
oral penicillin in secondary prevention of rheumatic fever--a systematic review. S Afr 










P a g e  | 23 
Part A: Research Protocol  
MÜLLER, I. et al., 1998. The effect of distance from home on attendance at a small 
rural health centre in Papua New Guinea. International journal of epidemiology, 27(5), 
pp.878–84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9839747. 
NKOMO, V. T. 2007. Epidemiology and prevention of valvular heart diseases and 
infective endocarditis in Africa. Heart, 93, 1510-9. 
ROBERTSON, K. A., VOLMINK, J. A. & MAYOSI, B. M. 2005. Antibiotics for the 
primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord, 
5, 11.  
SALEM, D.N. et al., 2006. Antithrombotic Therapy in Valvular Heart Disease — Native 
and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic 
Therapy. The Cardiopulmonary and Critical Care Journal. 
WALLENTIN, L. et al., 2010. Efficacy and safety of dabigatran compared with warfarin 
at different levels of international normalised ratio control for stroke prevention in atrial 
fibrillation: an analysis of the RE-LY trial. Lancet, 376(9745), pp.975–83. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20801496 [Accessed May 28, 2013]. 
WHO 2004. Rheumatic Fever and Rheumatic Heart Disease.  Report of a WHO Expert 
Consultation. 
WU, J.-R. et al., 2008. Medication Adherence in Patients Who Have Heart Failure: a 













P a g e  |  1 
Part B:  Literature Review 
 











P a g e  |  2 
Part B:  Literature Review 
Contents 
1. CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF ARF/RHD .............................................. 3
1.1 Pathogenesis .............................................................................................................................. 3
1.2 Clinical Manifestations of ARF and RHD ............................................................................... 5
1.3 Epidemiology of RHD ................................................................................................................ 6
2. PREVENTION .................................................................................................................................. 8
2.1 Primary and Secondary prevention ......................................................................................... 8
2.2  Tertiary Prevention ................................................................................................................. 11
3. LITERATURE REVIEW................................................................................................................. 13
3.1 Aim of this study...................................................................................................................... 13
3.2 The study question. ................................................................................................................. 13
3.3 Literature search strategy ....................................................................................................... 13
3.4 Summary of literature ............................................................................................................. 15
3.4.1 Anticoagulant Monitoring: INR Ratio and Therapeutic Ranges .................................. 15
3.4.2 Factors influencing INR maintenance within Therapeutic Ranges ............................. 16
3.4.3 Distance Decay as a factor for adherence ...................................................................... 18
3.4.4 Measuring distance decay using Geographical Information Systems (GIS) ............... 18
3.5 Summary and conclusions of the literature review. ............................................................ 19










P a g e  |  3 
Part B:  Literature Review 
 
1. CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF ARF/RHD 
1.1 Pathogenesis  
The mechanisms involved in the pathogenesis of Acute Rheumatic Fever (ARF) and 
Rheumatic Heart Disease (RHD) has been firmly established (Figure 1) (Guilherme & 
Kalil 2004) 
 
Figure 1:  Pathogenetic pathways in ARF and RHD (Carapetis, 
Mcdonald, et al. 2005) 
 
The initial event is a streptococcal pharyngitis (“Strep throat”) occurring in a 
susceptible host.  Strep throat infection is particularly prevalent amongst the 
marginalised, often subject to poor environmental conditions, overcrowded 
communities, poor housing conditions, poor nutrition and inadequate health services 
(Carapetis, Andrew C Steer, et al. 2005) (A C Steer et al. 2002).   Within 2 to 6 
weeks, should the throat infection be left untreated, ARF may develop.  ARF is an 
inflammatory disease which usually affects children between the ages of five and 
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It has been shown, at the immunological level, that the host antigens produced in 
response to the streptococcal infection in ARF patients, recognise the body’s own 
structures as foreign thereby initiating an inappropriate response of self-destruction 
(auto-immune).  This is due to the similarity of protein structures between the cell wall 
of the streptococcus bacteria and human joint tissue, brain tissues and heart valves, 
known as molecular mimicry (Guilherme et al. 2006).  Thus, repeated episodes of 
infection exacerbate the destruction of the tissues, causing permanent heart valve 
damage known as Rheumatic Heart Disease (RHD). Briefly, GAS antibodies cross 
react with glycoproteins present in the heart valves, cardiac myosin and laminin. This 
facilitates CD4+ and CD8+ T cell infiltration in the valves resulting, in the case of the 
valves, the appearance of vegetations on the surface (figure 2) (Guilherme et al. 
2007).More recently, a role for genetic susceptibility has been indicated in a recent 
study where it was shown that identical twins have a higher risk for concordance for 
ARF compared with non-identical twins (Engel et al. 2011). 
  
Figure 2:  ARF surgical specimen of the mitral valve showing 
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1.2 Clinical Manifestations of ARF and RHD 
 
Arthritis is the most common major  criterion for  ARF, occurring in 80% of patients.  
The joints most commonly affected include the knee, ankle, wrist, elbow, hip and 
shoulder.  The onset is sudden and  associated with local signs of the inflammatory 
response i.e. swelling, tenderness, redness and hotness. The pain and swelling 
caused by arthritis is migratory and by the time the affected joint is healing, another 
large joint becomes affected (Alsaeid & Majeed 1998).   
Carditis is the most important  manifestation of ARF with an incidence of the carditis 
of 40–50% in ARF patients. In the acute stage,  carditis can result in death or in 
severe morbidity caused by congestive heart failure. However, carditis can be 
subclinical and asymptomatic and detected only with colour Doppler 
echocardiography.  (Reményi et al. 2012) (Marijon et al. 2012).  Of note, carditis is 
the only sequel of ARF associated with long-term morbidity and of course mortality.   
The mitral valve is most commonly affected in the initial attack, causing mitral 
valvulitis.  The diagnostic clinical sign of mitral valvulitis (regurgitation) is the 
presence of a long, high pitched, blowing systolic murmur on auscultation.  Valvular 
damage can only be detected by the use of echocardiography (Carapetis, Mcdonald, 
et al. 2005). The diagnostic clinic sign for aortic valvulitis (regurgitation) is the 
presence of the basal diastolic murmur. The murmur is short and begins immediately 
after the second heart sound (Alsaeid & Majeed 1998).  In the acute phase, murmurs 
may also be due to endocarditis.  Endocarditis may affect only the endocardium and 
can be detected by the presence of significant murmurs on auscultatory investigation. 
ARF occurs around 3 weeks post the GAS infection (Meira et al. 2005).  An 
inappropriate immune response to a GAS infection may initiate vulvular damage. 
Even though the initial abnormal immune response may lead to severe valvular 
disease, RHD often results from reoccurring episodes of ARF which exacerbates 
valve damage (Carapetis, Andrew C Steer, et al. 2005). Clinical manifestations of 
chronic RHD include ventricular dysfunction and the development of aortic and mitral 
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1.3 Epidemiology of RHD  
 
A decline in the prevalence and incidence of ARF/RHD has been observed in the 
developed world over the last 150 years, as a result of improved living conditions and 
the extensive use of penicillin, not only for the treatment of GAS pharyngitis 
(Carapetis, Mcdonald, et al. 2005).  On the other hand, developing countries which 
make up 80% of the world’s population continue to experience high cases of 
ARF/RHD.  ARF/RHD is the most common acquired heart disease affecting children 
and young adults in the world (Carapetis, Mcdonald, et al. 2005). 
ARF and RHD together, affects around 15.6 million people worldwide, 2.4 million of 
whom are children aged five to fourteen years old residing in developing countries. 
Furthermore, ARF/RHD leads to an estimated 350 000 deaths annually  (Carapetis, 
Andrew C Steer, et al. 2005)(Carapetis, Steer et al. 2005).  0.3 – 3% of people 
progress to develop ARF if a streptococcus group A throat infection goes untreated. 
Approximately 40 – 60% of episodes of ARF results in RHD (Engel et al. 2009).  
Figure 3 represents the global burden of RHD.  It clearly demonstrates that Africa, 
which contains 10 % of the world’s population, has a high share of people living with 
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RF/RHD. In 2002, half of the 2.4 million children living with RF/RHD reside in sub-
Saharan Africa indicating that the disease is extremely prevalent here (Carapetis, 
Andrew C Steer, et al. 2005).  Recent work from Seckeler et al. confirms the increase 
of RHD on the african continent (Figure 4) (Seckeler & Hoke 2011).  
 
Figures for South Africa are scant with the majority of studies having been reported 
before the advent of echocardiography.  In a 2002 report from a paediatric cardiology 
conference hosted by the department of health, a consensus opinion was that South 
Africa was in the midst of an ARF epidemic despite national guidelines and 
recommendations for antibiotic prevention of the disease (Department of Health SA 
2002).  Furthermore, even though high numbers are being observed, there appears 
to be poor administration of the ARF notification system and underreporting of ARF 
cases by health care professionals in South Africa (Nkgudi et al. 2006).   
 
  
Figure 4. Map showing reported worldwide prevalence of RHD from 1991 
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2. PREVENTION
2.1 Primary and Secondary prevention 
ARF and the development of RHD is almost entirely preventable using strategies that 
are cheap and cost effective.  The World Health Organisation recognises ARF as 
being an illness of epidemic proportions and it being the most common cause of 
acquired heart disease affecting children in the world (World Health Organisation 
2004).   
The early detection, correct diagnosis and correct treatment of GAS pharyngitis with
penicillin, prevents the first attack of ARF. This is referred to as primary prevention
(Marijon et al. 2012). If the first episode of ARF is not prevented, further episodes of 
a GAS sore throat, which increases the chances of developing RHD needs to be
avoided. This is known as secondary prevention (Manyemba & Mayosi 2003).
Intramuscular long-acting penicillin is administered as prophylaxis to prevent further 
episodes of ARF and worsening of RHD. Table 1 details the WHO’s guidelines for 
primary and secondary prevention strategies for the treatment of ARF/RHD. Table 2












Table 1:  WHO’s guidelines for primary and secondary prevention of RF/RHD (World Health Organisation 2004). 
Antibiotic Administration  Dose 
Primary Prevention 
Benzathine benzylpenicillin Single intramuscular injection 1200000 units 
600000 units <27kg 
Phenoxymethyl penicillin 
(Penicillin VK) 
Orally 2-4 times/day for 10 full days Children: 250mg bid or tid. Adolescents or adults: 250mg tid or 
qid, or 500mg bid 
Amoxicillin Orally 2-3 times/day for 10 full days 25-50mg/kg/day in three doses. Total adult dose is 750-
1500mg/day 
First-generation cephalosporins Orally 2-3 times/day for 10 full days Varies with agent 
Erythromycin ethylsuccinate Orally 4 times/day for 10 full days Varies with formulation. Available as the stearate, 
ethylsuccinate, estolate or base 
Secondary Prevention 
Penicillin Intramuscular injection. Every 4 
weeks (28 days) 
Children: < 20kg: 600 000 U Children >20kg or adults: 1,200 
000U 
Penicillin VK Orally bd 250 mg bd 
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Table 2:  Period of dose for secondary prevention (World Health Organisation 2004). 
 
Category Duration of prophylaxis 
All persons with ARF with no or mild carditis Minimum of 10 years after most recent episode or age 21 
All persons with ARF and moderate carditis Minimum of 10 years after most recent episode or age 30 
All persons with ARF and severe carditis Minimum 10 years after most recent episode or age 30 and then specialist 
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2.2  Tertiary Prevention 
Once damage to the valves has occurred, valve surgery may be necessary to correct 
cardiac function (Marijon et al. 2012).  This is warranted when patients become 
symptomatic as a result of severe valvular lesions (Bonow et al. 2006).  Treatment 
options include vulvular repair or replacement with either mechanical or biological 
(prosthetic) valves (Figure 5).   
Figure 5:  mechanical (left) and biological prosthetic valves (Advanced Practice 
Strategies n.d.) (Ostrovsky 2007) 
 
Valvular replacement carries the risk of blood clot formation and / or embolism which 
may result in stroke (Salem et al. 2006).  To prevent this complication, anticoagulant 
drugs such as warfarin are prescribed (Salem et al. 2006).  Anticoagulants e.g. 
Warfarin, interfere with the availability of vitamin K, which plays a vital role in the natural 
clotting process of the body, and in doing so, prolongs the normal prothrombin time (PT) 
(Hirsh et al. 2013).  The liver produces blood clotting proteins which are dependent on 
vitamin K to initiate the clotting process (Lefkowitz 2008) (Figure 6).   
Anticoagulant levels are measured using the International Normalised Ratio (INR). It is 
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. 
abnormal bleeding or excessive clot formation due to inadequate levels of 
anticoagulants of the blood. Maintenance of anticoagulant levels within the 
recommended therapeutic range ensures that therapies are effective in their function to 
reduce the risk of stroke and other complications in RHD patients (Kuruvilla & Gurk-
Turner 2001).   
Various factors for non-adherence to health-related interventions and monitoring have 
been suggested by the WHO, including distance decay (Figure 6) (Wu et al. 2008).  
Thus, it is imperative to identify those factors which serve as facilitators and barriers to 
adherence, in an attempt to reduce the risk of morbidity and mortality related to 
anticoagulation therapy. 
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3. LITERATURE REVIEW
3.1  Aim of this study 
The objective of this literature review is to establish whether the maintenance of 
therapeutic ranges in adult rheumatic heart disease patients, on anticoagulant therapy, 
is correlated with the distance travelled from their residence to the clinic where INR 
monitoring takes place. 
3.2 The study question. 
In adult rheumatic heart disease patients on anticoagulant therapy, is the maintenance 
of therapeutic ranges as measured by INR monitoring, influenced by road travel
distance from patients’ residence to their treatment clinic?
3.3 Literature search strategy 
We searched the major databases including PubMed, ISI, and web of knowledge. We
supplemented the search suing Google scholar and by scanning reference lists of 
potential papers. Table 3 details the search strategy as used in the PubMed database
together with the number of articles found; the search was modified accordingly for
searching other databases.  
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Table 3:  Details of search strategy indicating results from the PubMed database.*   
 
 SEARCH TERMS PUBMED RESULT 
1 RHEUMATIC HEART DISEASE 3195 
2 RHEUMATIC FEVER 6261 
3 #1 OR #2 8705 
4 CONCORDAN* 38140 
5 ADHEREN* 87190 
6 #4 OR #5 124870 
7 INR 5103 
8 INTERNATIONAL NORMALISED RATIO 490 
9 INTERNATIONAL NORMALIZED RATIO 3901 
10 #7 OR #8 OR #9 6872 
11 ANTICOAGULA* 60389 
12 DISTANCE  138293 
13 #3 AND #11 157 
14 #3 AND #6 53 
15 #12 AND #6 5 
16 #12 AND #3 18 
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3.4  Summary of literature 
 
3.4.1  Anticoagulant Monitoring:  INR Ratio and Therapeutic Ranges 
Therapeutic ranges are monitored using the so-called International Normalized Ratio 
(INR).  The INR is a laboratory calculation which compares the clotting times in patients 
on anticoagulants with those of healthy individuals, represented as a ratio. Therapeutic 
levels representing normal values are between 2.00 – 3.00 for patients with biological 
prosthetic valves and 2.5 – 3.5 for patients with mechanical prosthetic valve 
replacements (Hirsh et al. 2013).  Too high an INR value indicates a risk for abnormal 
bleeding, while too low a value indicates the patient is not protected against clot 
formation.  It is thus important to monitor patients’ INR values on a regular basis to 
ensure that anticoagulant levels are maintained within the recommended ranges so as 
to ensure that therapies are effective in their function to reduce the risk of stroke and 
other complications in RHD patients. Anticoagulant treatment requires regular 
laboratory-guided adjustments of the dose as response to treatment is affected by 
interactions with food and drugs (Wallentin et al. 2010). 
The benefit of valve repair compared to replacement has been shown in many studies 
to be associated with favourable long-term outcome, reduced mortality rates and an 
improved quality of life in RHD children  (Ciss et al. 2009).   However, in instances 
where valve repair is not feasible, the option of prosthetic valve replacement is 
unavoidable.  The choice for type of prosthesis is important and factors such as age, 
gender, geographical area, etc need to be considered in the context of likelihood of 
defaulting in adherence to anticoagulant treatment (Ferratini et al. 2013) (Marijon et al. 
2012).  Biological prosthesis in the mitral valve in young patients is prone to early 
deterioration, but on the other hand is associated with a lower incidence of thrombosis.  
A recent review concluded that in scenarios where the therapeutic range is successfully 
maintained in young people, mechanical prosthetic valve replacement should be 
preferred, even in young females who are now vulnerable to pregnancy risks  (Ferratini 
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3.4.2   Factors influencing INR maintenance within Therapeutic Ranges  
The safety and effectiveness of anticoagulant therapy is crucially dependant on 
maintaining the INR within the therapeutic range (Hirsh et al. 2003).  In RHD patients, 
the lack of concordance to monthly INR monitoring can result in complications such as 
stroke due to sub-therapeutic INR levels going unnoticed; in a cohort study evaluating 
the effect of warfarin on the risk of thromboembolism in 11,526 adult patients in atrial 
fibrillation of which 6,320 were in anticoagulant treatment, Go et al reported that during 
follow-up, there were 148 thromboembolic events, 141 of which were attributed to 
ischemic stroke among those on anticoagulant therapy.  Lower rates of 
thromboembolism were observed amongst anticoagulant users with risk factors for 
stroke which included prior stroke, hypertension, diabetes, coronary heart disease and 
those 75 years and older (Go et al. 2013). 
A number of factors for non-adherence / non-concordance as regards medication in 
general has been proposed, an explanation of which has been presented in the WHO’s 
multidimensional adherence model, figure 7 (Wu et al. 2008). 
Figure 7: WHO's multidimensional adherence model and 
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Briefly, the five broad categories which are described include socio-economic factors 
such as finance constraints, patient/provider relationship dynamics, the severity of the 
condition, the complexity of the treatment and also patient-related factors.  Thus, it is 
imperative to identify those factors which serve as facilitators and barriers to adherence, 
in an attempt to reduce the risk of morbidity and mortality related to anticoagulation.  
Medication adherence is largely attributed to the patient with only around 50 percent of 
information discussed with the patients at the time of consultation being recalled on a 
later occasion (Sabaté 2003)(Schillinger et al. 2013).  Furthermore, patients with low 
literacy levels may be unable to read dosage instructions and information on a medicine 
bottle (Parikh et al. 1996).  
It has been previously shown that poor adherence to anticoagulant therapy such as 
warfarin, is a major contributor to non-therapeutic anticoagulation  (Cavallari et al. 2009) 
(Palareti et al. 2005).  In a study conducted in Chicago in 2009, it was shown that 
patients who were provided with a monthly medication organiser improved warfarin 
adherence and significantly increased patients’ length of time within INR therapeutic 
range  (Nochowitz et al. 2009). Even though this intervention improved adherence, INR 
values still remained outside of the therapeutic range about 40 percent of the time.  
Thus the need for further studies are warranted to investigate additional interventions 
which could perhaps be used in combination with strategies that have already been 
shown to improve control and stabilise anticoagulation.     
Many studies have examined various interventions to stabilise anticoagulation. One of 
such studies indicated how the use of computer software to track INR results and 
recommend changes in the dosage of anticoagulant treatment, as well as patient self-
monitoring can be used to improve anticoagulation control and in so doing, reduce 
complications associated with INR measurements outside of the therapeutic range  
(Chiquette et al. 1998) (Beyth et al. 2000).  These strategies are however, associated 












P a g e  |  18 
Part B:  Literature Review 
 
3.4.3  Distance Decay as a factor for adherence 
Geographical factors such as distance from the patients’ residence to their health care 
facility (defined as “distance decay”), have been shown to be a significant barrier to 
access (Gabrysch & Campbell 2009).  Briefly, as distance to reach services increase, 
the rate of service use decreases, resulting in a geographical health care disparity 
(Freehauf et al. 2013) (Müller et al. 1998).  
 
3.4.4 Measuring distance decay using Geographical Information Systems (GIS) 
While epidemiologists have traditionally used maps when analyzing associations 
between location, environment, and disease (Gesler 1986), the application of GIS 
technology has recently been considered as an important and new component in many 
epidemiological and health projects (Cromley 2003).  GIS technology aids the 
epidemiologist in understanding the subject under investigation to initiate interventions 
promptly.  GIS presents statistical data in a spatially referenced manner through maps.   
In particular, GIS enables the epidemiologist to: 
 Determine geographic distributions of disease 
 Observe surveillance and control infectious diseases 
 Determine epidemics, monitor the growth and assists in the best approach with 
regard to intervention strategies 
 Analyse spatial and temporal trends of disease, and 
 Determine the population at risk by creating risk maps using the buffer tool using 
the GIS. 
 
GIS is particularly well suited for studying these associations because of its spatial 
analysis and display capabilities.   
In a recent study conducted in Vietnam, GIS was used to investigate the effect of 
distance decay on delivery care utilisation (Målqvist et al. 2010).  This study on neonatal 
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nearest health care facility, specifically investigating the influence of distance on 
patterns of perinatal health care utilisation. It showed an increased risk of neonatal 
mortality among mothers living farthest away from a health facility.  Similarly, another 
GIS-based study conducted in Kenya found that younger children and children with 
more severe illnesses travelled a further median distance to a health facility compared 
with older children with less serious illnesses;  the rate of clinic visits decreased linearly 
at 0.5km intervals and stabilised after 4 kilometres  (Feikin et al. 2009). 
3.5 Summary and conclusions of the literature review. 
Maintenance of INR therapeutic ranges in adult patients on anticoagulant therapy is
dependent on a number of factors, including adherence to anticoagulant therapy such
as warfarin, which is influenced by geographical, socioeconomic and patient-related
factors to name a few. Specifically, the distance travelled from patients’ residence to
the clinic where INR monitoring takes place (so called, distance decay) has been shown
to be a barrier to patients’ attendance at health care facilities.
Distance may play a significant role in adherence to INR monitoring requirements
amongst RHD patients on anticoagulant therapy. This semi-structured systematic
review of the literature revealed that no studies exist on the effect of distance decay on
the maintenance of INR therapeutic ranges among RHD patients. Thus, primary
studies to investigate this phenomenon is warranted. 
The primary aim of this thesis therefore, was to evaluate the effect of distance on the
maintenance of INR therapeutic ranges amongst adult RHD patients on anticoagulant
therapy. It is anticipated that the results of this study will serve to inform programmes
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 ABSTRACT  
 
Background: Lack of adherence to International normalised ratio (INR) monitoring in 
rheumatic heart disease (RHD) patients is a contributor to stroke and other 
complications. This population-based observational study investigated whether 
distance affects the maintenance of INR within therapeutic ranges in RHD patients. 
Methods: Patient residential addresses and their attending clinics, together with 
laboratory INR results were extracted from the REMEDY RHD Registry database. 
Addresses were converted to geographical coordinates and verified in ArcGIS 10®.  
ArcGIS 10® and Google Maps® were used for spatial mapping and obtaining shortest 
road distances respectively.. The travel distance between individual residential 
addresses and referral clinics was compared to the average of three INR readings of 
patients and compared with therapeutic ranges recommended by guidelines. 
Results:  RHD patients (n=133) reside between 0.2 km and 50.8 km (median 
distance, 3.60 km) from one of 33 referral clinics. Patients who maintained their INR 
within recommended therapeutic levels travelled a shorter median distance to their 
designated INR clinic (in range = 3.50 km versus out of range = 3.75 km, p=0.78).  
This trend was consistent within the mechanical valve replacement subset of patients 
(n=105) (3.50 km versus 3.90 km, p=0.81) but contrasted with patients who had not 
had mechanical valve replacements (n=28) where the patients who maintained 
therapeutic levels travelled a further median distance to designated clinics (3.45 km 
versus 2.75 km, p=0.84).  These non-statistically significant trends were consistent 
when considering patients attending community-based clinics as a subset.  Patients 
with mechanical valves were significantly less likely to be within their INR range (O.R., 
0.32; 95% CI, 0.11; 0.86).  Again, this observation was consistent amongst the 
community-based clinics. (O.R. 0.28; 95% CI, 0.08; 0.89);  however, this significant 
association was not observed at any of the individual clinics.  
Conclusion: Distance did not have an effect on the maintenance of INR within 
therapeutic range amongst RHD patients enrolled within our study in Cape Town.  
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BACKGROUND 
 
Rheumatic heart disease (RHD), a condition characterised by permanent damage to 
heart valves, is a consequence of repeated episodes of acute rheumatic fever (ARF) in 
patients with failed or non-existent secondary prophylaxis (Nkomo 2007).   Over recent 
decades, industrialised countries have experienced a significant decline in the 
prevalence of RHD through improved living conditions and the use of penicillin for the 
treatment of Group A streptococcal pharyngitis, the initial event in the disease 
pathogenesis (Carapetis et al. 2005).   In contrast, developing countries which account 
for 80% of the world’s population, continue to experience high cases of RHD;  RHD 
and its precursor, acute rheumatic fever (ARF) are the most common diseases 
affecting children and young adults in the world  (Carapetis et al., 2005).  Primary and 
secondary prevention strategies to prevent disease progression, have been 
implemented in many parts of the world as per the World Health Organisation (WHO) 
recommendations  (World Health Organisation 2004). Primary prevention specifically 
targets the correct management of GAS pharyngitis with penicillin, to avoid the later 
development of ARF (Robertson et al. 2005).  If the first episode of ARF is not 
prevented, further episodes of ARF are prevented through the administration of a 
monthly prophylactic penicillin injection (known as secondary prevention) (Manyemba 
& Mayosi 2003).     
 
A small percentage of patients may become symptomatic as a result of severe valvular 
lesions (Bonow et al. 2006), warranting corrective heart valve surgery (Marijon et al. 
2012).  Treatment options include valvular repair or replacement with either 
mechanical or biological (prosthetic) valves.   Valvular replacement however, carries 
the risk of blood clot formation and / or embolism, which may result in stroke (Salem et 
al. 2006).  To prevent this complication, anticoagulant drugs such as warfarin are 
prescribed.  Warfarin acts by interfering with the availability of vitamin K, which is 
essential to initiate the clotting process, thereby prolonging the normal prothrombin 
time (PT) and preventing excess clotting (Hirsh et al. 2013)) (Lefkowitz 2008).  
Anticoagulation therapy with warfarin is highly effective at reducing the risk of stroke, 
but is associated with monitoring costs and a higher risk of haemorrhage compared 
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Anticoagulant treatment requires regular laboratory-guided adjustments of the dose as 
response to treatment is affected by interactions with food and drugs (Wallentin et al. 
2010).  Monitoring is done through the so-called International Normalized Ratio (INR), 
which represents the comparison of clotting times in patients who have been 
prescribed anticoagulants against the clotting times in healthy individuals.  Evidence-
based clinical guidelines indicate INR therapeutic level ranges for patients, which are 
between 2.00 – 3.00 for patients without valve replacements and 2.5 – 3.5 for patients 
with mechanical prosthetic valve replacements (Hirsh et al. 2013).   Too high an INR 
value indicates a risk for abnormal bleeding, while too low a value indicates that the 
patient is not protected against clot formation.   
 
The safety and effectiveness of anticoagulant therapy is crucially dependent on 
maintaining the INR within the therapeutic range (Hirsh et al. 2003).  In RHD patients, 
the lack of concordance to monthly INR monitoring can cause complications such as 
stroke; in a cohort study evaluating the effect of warfarin on the risk of 
thromboembolism in 11,526 adult patients in atrial fibrillation of which 6,320 were in 
anticoagulant treatment, Go et al reported that during follow-up, there were 148 
thromboembolic events, 141 of which were attributed to ischemic stroke among those 
on anticoagulant therapy.  Lower rates of thromboembolism were observed amongst 
anticoagulant users with risk factors for stroke which included prior stroke, 
hypertension, diabetes, coronary heart disease and those 75 years and older (Go et 
al. 2013).  Various factors for non-adherence to health-related interventions and 
monitoring have been suggested by the WHO, including distance decay (Wu et al. 
2008) (Gabrysch & Campbell 2009).  Distance decay is a term given to describe a 
phenomena observed between two locations. As distance to reach services increase, 
so does the rate of service use decrease causing geographical health care disparities 
(Freehauf et al. 2013).  A systematic review of the literature revealed that there exists 
no studies on the effect of distance decay on the maintenance of therapeutic ranges 
among RHD patients, thus supporting the need for primary studies to investigate this 
phenomenon.    
 
In a recent study conducted in Vietnam, GIS was used to investigate the effect of 
distance decay on delivery care (Målqvist et al. 2010).  The study found an increased 
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Similarly, another GIS-based study conducted in Kenya found that younger children 
and children with more severe illnesses travelled a further median distance to a health 
facility compared with older children with less serious illnesses;  the rate of clinic visits 
decreased linearly at 0.5km intervals and stabilised after 4 kilometres  (Feikin et al. 
2009).  
The primary aim of this thesis was to evaluate the effect of distance on the 
maintenance of INR therapeutic ranges amongst RHD patients on anticoagulant 
therapy.  Specifically, this study aims to investigate whether the distance of a patient’s 
residence from their referral or treatment clinic impacts on maintaining INR levels
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METHOD 
Study design 
This was a population-based observational sub-study nested within the Groote Schuur 
Hospital cohort of the REMEDY study, a multicenter, prospective hospital-based RHD 
registry (Karthikeyan et al., 2011). The REMEDY project aims to provide 
comprehensive, contemporary data on patients with RHD so as to aid the 
development of strategies to prevent and manage RHD and its complications. 
Recruitment and enrolment 
All Groote Schuur Hospital patients diagnosed with RHD and enrolled into the
REMEDY study, were eligible to participate in the study. Patients were excluded if 
their data were incomplete at their 12-month follow-up visit, or if they resided outside
of the Cape Metropole area which is located in the Western Cape province of South
Africa. The Western Cape is divided into one metropolitan municipality (City of Cape
Town) and five district municipalities. 
Data collection 
Patient data including demographic details and residential addresses and clinical data
such as diagnosis of RHD, INR readings and referral INR clinics were extracted from
REMEDY patient records and captured into a purpose-designed database. Patient
addresses were converted to geographical coordinates obtained from Google Earth®, 
while government clinics were mapped using information supplied by the Department
of Surveying and Mapping in Mowbray, Cape Town. 
Geographical Information Systems 
This study utilized Geographical Information System (GIS) software, ArcGIS 10®, for 
capturing, manipulating, managing, analysing and displaying spatial and non-spatial 
data.  In brief, GIS overlaps layers of information within a geographical area to give a 
better understanding from a composite viewpoint (Evans, 1997).    Information about 
geographical features (roads, boundaries etc.) was accessed from the ESRI database 
(https://www.arcgis.com).  Data were projected in the Universal Transverse Mercator 
(UTM) system.  The shortest road travel distances between homes and the health 
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entered into the study database (https://maps.google.co.za/maps?hl=en).   Linear 
distances between the patients’ home and closest health facility were calculated using 
the “near” function in the “proximity” toolbox in ArcMap 10®.  The Geocoded addresses 
were checked in ArcGIS for errors in coordinate data.  Distances mentioned are all 
one-way distances.   
 
Data analyses 
Statistical analyses and data handling were performed using STATA® version 11 and 
ArcGIS® version 10.  INR readings were evaluated as a whole, and stratified according 
to valve replacements type, since bioprosthetic and mechanical valves differ with 
respect to INR therapeutic ranges.  Pearson’s chi-squared test and Mann-Whitney U 
test was used for group comparisons.  A p-value of < 0.05 was considered significant.  
The road travel distance between individual residential addresses and referral clinics 
was compared with the average of the latest three INR measurement readings of the 
patient.  Where appropriate, analyses were repeated excluding GSH hospital, given 
that it is the only tertiary hospital amongst the community-based clinics.  
 
Ethical Approval 
This research project was part of a larger research project that has already been 
approved by the Human Research Ethics Committee at the University of Cape Town 
(HREC 028/2006).  This work contributed to the analysis component of the registry, 
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RESULTS 
 
Of 500 patients enrolled at GSH in the REMEDY database, 133 patients met the 
inclusion criteria (i.e. patients who had complete INR data and, for whom full address 
details were available).  Eighty-three percent of the cohort was female and 79% of 
patients (n=105) had had mechanical valve replacements.  Co-morbidities included 
hypertension (27%), stroke (25%) and diabetes (19%) (Table 1).    Of the 224 patients 
not meeting the inclusion criteria, 185 (83%) were female and 81 (36%) had had 
mechanical valve replacement, while the median age was 46 years (16 – 79). 
 
 
Table 1: Baseline characteristics of participants   
 N % 
GSH patients in REMEDY 500  
Patients with >12 month follow-up  357   
Patients with >12 month follow-up for whom data 
are available 
133  
Average Age 53 years (+/- 1.25)  
Female 110 83% 




Comorbidities n/N % 
Hypertension 27/99 27% 
Stroke 28/111 25% 
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Figures 1 and 2 represent the spatial orientation of the RHD patients’ residence and 
the INR clinics in the Cape Metropole region. INR monitoring was conducted among 
33 clinics across the Cape Metropole.  Road distances were not normally distributed; 
the median distance between the patient’s residences and their respective clinics was
3.60 km (range, 0.2km – 50.8km).  Patients attending Groote Schuur Hospital (GSH), 
the only tertiary hospital included among the INR clinics, travelled a median distance 
of 18.2 km (1.6 km - 50.8 km).   
Figure 2 displays the clinics utilized by RHD patients for INR monitoring as well as 
clinics not currently used for INR monitoring. The geographical distribution of these 
clinics indicate that patients could instead be utilizing clinics closer to their residences 
Figure 1: Map of the Cape Metropole showing patients residences and the clinics
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Table 2 details eight clinics utilized by 3 or more patients for INR monitoring, indicating 
the number of patients who maintained therapeutic levels according to whether or not 
they had had a mechanical valve replacement.  Overall, patients with mechanical 
valves were significantly less likely to be within their INR range compared with patients 
who had no or bioprosthetic valve replacements (O.R., 0.32; 95% CI, 0.11; 0.86).   
This observation was consistent amongst the community-based clinics after excluding 
GSH (O.R. 0.28; 95% CI, 0.08; 0.89).  However, this significant association was not 
observed at any of the individual clinics. Amongst all patients, irrespective of valve 
replacement or not, there was no difference in maintenance of INR within therapeutic 
range in patients from GSH versus those from community based clinics. (O.R., 1.44; 
95% CI, 0.62; 3.41). 
 
Figure 2: Map showing patients’ residences, their designated INR clinic and the 
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Table 2: Shortest median road distance from patients’ home to health facilities 
Obs No in INR range Median KM
MVR = No MVR = Yes
 ALL CLINICS 133 20/28 (71) 47/105 
(45)
3.60 (0.2 - 50.8) 
ǂ Excluding GSH 98 15/21 (71) 32/77 (42) 2.60 (0.2 – 27.3) 
Clinic Attended (> 3 patients)
GSH 35 5/7 (71) 15/28 (54) 18.2 (1.6 - 50.8) 
Dr Abdurahman CHC 10 - 3/10 (30) 2.95 (1.0 – 5.4)
Mitchell’s Plain CHC 21 1/4 (25) 7/17 (41) 2.8 (1.2 - 5.6) 
Heideveld CHC 10 1/2 (50) 3/8 (38) 2.75 (1.6 - 6.5) 
Hanover Park CHC 8 1/1 (100) 4/7 (57) 1.1 (0.2 – 9.1)
Lady Michaelis 5 1/2 (50) 1/3 (33) 6.4 (1.8 – 14.0)
Woodstock CHC 4 1/2 (50) 1/2 (50) 1.55 (0.4 – 14.9)
Obs, observations; No, number; KM, kilometers; MVR, mechanical valve replacement; GSH, Groote Schuur Hospital; CHC, community health clinic
ǂGSH is a tertiary facility and is not used for routine INR monitoring.
Among all the patients in our cohort, those who maintained their INR within 
recommended therapeutic levels travelled a shorter median distance to their
designated INR clinic (3.50 km versus 3.75 km). (Table 3). However, this observation
was not statistically significant (P=0.78). This trend was also observed within the
mechanical valve replacement subset of patients (n=105) (in range = 3.50 km versus
out of range = 3.90 km, p=0.81). This trend however, contrasted with patients who
had not had mechanical valve replacements (n=28) where the patients who
maintained therapeutic levels travelled a further median distance to their designated
clinics (3.45 km versus 2.75 km, p=0.84). This probably suggests that distance is not a
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Table 3: Median shortest road travel distance from patients’ home to health facility, 
overall and by valve replacement type 
 
 n (%) Median KM 
All patients   
Out of range 66 (49.6) 3.75 (0.4 - 50.8) 
In range 67 (50.4) 3.50 (0.2 – 30.8) 
Total 
 
133 (100) P=0.78 
Mechanical Valve = Yes   
Out of  range  58 (55) 3.90 (0.4 – 50.8) 
In range 47 (45) 3.50 (0.2 – 30.8) 
Total 105 (100) P=0.81 
Mechanical valve = No   
Out of range 8 (29) 2.75 (1.2 – 18.2) 
In range 20 (71) 3.45 (1.0 – 24.0) 
Total 
 










P a g e  | 14 
Part C: Journal Manuscript 
Figure 3 depicts the distance of the closest clinic relative to the patient’s home
address: clinics are indicated by red crosses and the graduated dots represent the 
scale (based on size and colour ranging from yellow (0 – 0.5 km) to red (1.5 – 2.8 km) 
of the distance to the nearest clinic.  The median distance from the patients’ residence 
to the closest clinic is 0.67 km (0.08 – 2.80).    
Among those patients attending community-based clinics (n=98), there was no 
difference in the median travel distance to their designated INR clinic between patients 
who maintained their INR therapeutic range and those who failed to maintain their 
therapeutic range (p=0.66) (Table 4).  Patients who have had mechanical valve 
replacements (n=77) and who maintained their recommended INR therapeutic range, 
travelled a shorter median distance to their designated INR clinic (2.50km versus 
2.90km);  this observation was not statistically significant (p=0.47).  In contrast, 
patients who did not have mechanical valve replacements (n=21) and maintained INR 
Figure 3: Map showing the distance to the closest clinic represented by the
graduated symbols 
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therapeutic levels, tended to travel a further median distance (2.90km verses 1.90km) 
compared with those who failed to maintain therapeutic ranges;  however, this finding 
did not reach significance (p=0.53).  
 
Table 4: Shortest median road travel distance from patients’ home to community-
based clinics according to mechanical valve replacement statusǂ  
 n (%) Median KM 
All patients   
Out of range 51 (52) 2.60 (0.4 – 27.3) 
In range 47 (48) 2.60 (0.2 – 15.0) 
Total  98 (100) P=0.66 
Mechanical Valve = Yes   
Out of range 45 (58) 2.90 (0.4 – 27.3) 
In range 32 (42) 2.50 (0.2 – 15.0) 
Total          77 (100) P=0.47 
Mechanical valve = No   
Out of range 6 (29) 1.9 (1.2 – 14.0) 
In range 15 (71) 2.90 (1.0 – 11.4) 
Total           21 (100) P=0.53 
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DISCUSSION 
Out of pocket expenses has been identified as a barrier to adherence (Eaddy et al. 
2012), thus longer travel distances implies more expenses.  In this study, we 
examined the association between distance from an RHD patient’s residence to their 
designated INR clinic, and the maintenance of INR within recommended therapeutic
levels. There was no difference in the median distance between the residence of 
patients who maintained their INR readings within therapeutic range versus those who
did not. (3.50 km versus 3.75 km; p=0.78). Given that INR therapeutic ranges differ 
according to whether patients had undergone a mechanical valve replacement (MVR)
or not (i.e. 2.0 – 3.0 for no or biological valve replacement, and 2.5 – 3.5 for
mechanical valve replacement), we also considered MVR patients separately. There
was a non-significant trend of INR therapeutic levels with travelling a shorter distance
in MVR recipient patients (p=0.81). By contrast, in non-MVR patients in good control
travelled further distances than those out of control. These trends probably reflect a
play of chance in a context in which distance did not play a role in INR control in Cape
Town. 
Participants for our study needed to have at least one INR reading, be within the
geographical metropolitan area served by the hospital and have complete address
information. In comparison to those excluded, gender and mean age were similar
while the proportion of patients with mechanical valve replacements was noticeably
different (79% vs 36% respectively). This may represent selection bias, and thus, a
closer evaluation incorporating qualitative methods would be warranted in the future.
GSH is a tertiary hospital and the INR clinic deals particularly with patients who have 
been newly assigned to anticoagulant treatment.  Thus, patients are more closely 
monitored during the initial phase while attempting to establish the correct dosing 
regimen;  thus, results from GSH may bias our findings.   Excluding the GSH patients 
(n=35) and considering only those patients attending community-based clinics showed 
a trend that mechanical valvular replacement patients who maintained their INR 
therapeutic range travelled a shorter median distance compared with those who failed 
to maintain their therapeutic range.  This observation was consistent amongst the 
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in both instances (p=0.47 and p=0.53 respectively).  The finding of non-MVR patients 
maintaining their INR ranges despite living further away was also seen in this group.  
 
We made use of both linear and road distances in our analysis.  The shortest road 
travel distances between patients’ home and health facilities were measured using 
Google Maps®.  To determine the median distance to the closest health facility from 
patients’ residence, we made use of linear distance measurement.  The median 
distance to the closest health facility was 0.67 kilometers (Straight-line distance), while 
the median road distance patients actually travelled to their treatment health facility 
was 3.60 kilometers. In our study, distance did not have an effect on the maintenance 
of INR control.  Even though patients who maintained their INR therapeutic range 
travelled a shorter median distance compared with patients who failed to maintain their 
INR therapeutic range, this observation failed to reach statistical significance (P>0.05). 
 
Our results contrasts with studies which evaluated the effect of patients’ travel 
distance on utilization of health services.   A recent study on neonatal mortality 
conducted in Vietnam, showed an increased risk of neonatal mortality among mothers 
living farthest away from a health facility  (Målqvist et al. 2010).  In another, conducted 
in Kenya, it was found that younger children and children with more severe illnesses 
travelled a further median distance to a health facility compared with older children 
with less serious illnesses;  the rate of clinic visits decreased linearly at 0.5km intervals 
and stabilised after 4 kilometres  (Feikin et al. 2009).   
 
One limitation of this study could be attributed to the sample size. Even though a trend 
was seen among patients who have had mechanical valve replacements, the 
association failed to reach statistical significance.  Another limitation to this study could 
be attributed to the geographical measurement. Straight-line distances were used to 
calculate the distance to the nearest clinic from patient’s residences.  Moreover, 
another limitation may be the relatively short median distances travelled in Cape 
Town. It is possible that distance decay may be a factor in median distances of more 
than 50km’s.  Lastly, there are many factors which influence adherence.  This study 
only managed to focus on distance, given the scope of the data in the registry.  
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however, most patients attending the public service use public transport.  The informal 
taxi network is extensive and travel times per km are largely uniform.  
The extent to which the straight-line distance measurement is used as a proxy for true 
distance is sometimes questionable.  This raises concern when a particular 
geographical area of study has diverse features, for example, vast mountainous areas 
where there is limited road access.  In this study, the geographical area has a good 
road infrastructure and is not affected by diverse geographical features.  Furthermore, 
straight-line distances have previously been used in many studies including the 
Vietnam and Kenya studies discussed previously. 
CONCLUSION 
Distance decay did not have an effect on maintenance of patients’ INR therapeutic
ranges. The median distance that patients in our cohort could be travelling however, is 
less than 1 kilometer suggesting that if patients attend a clinic within their residential
area or a clinic nearest to their homes, it could reduce travelling time and out of pocket
expenses associated with transport cost to access healthcare. . If patients utilize a
clinic in their neighborhood or nearest to their residence, they could be reducing their
expenses, which may improve adherence related issues. Furthermore, the load on
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Assistance with the process of manuscript preparation and submission is available 
from BioMed Central customer support team. 
We also provide a collection of links to useful tools and resources for scientific 
authors on our Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript 
document:  
 Microsoft word (DOC, DOCX) 
 Rich text format (RTF) 
 Portable document format (PDF) 
 TeX/LaTeX (use BioMed Central's TeX template) 
 DeVice Independent format (DVI) 
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if 
you use TeX format. During the TeX submission process, please submit your TeX 
file as the main manuscript file and your bib/bbl file as a dependent file. Please also 
convert your TeX file into a PDF and submit this PDF as an additional file with the 
name 'Reference PDF'. This PDF will be used by internal staff as a reference point to 
check the layout of the article as the author intended. Please also note that all 










If you have used another template for your manuscript, or if you do not wish to use 
BibTeX, then please submit your manuscript as a DVI file. We do not recommend 
converting to RTF. 
For all TeX submissions, all relevant editable source must be submitted during the 
submission process. Failing to submit these source files will cause unnecessary 
delays in the publication procedures. 
Publishing Datasets 
Through a special arrangement with LabArchives, LLC, authors submitting
manuscripts to BMC Public Health can obtain a complimentary subscription to
LabArchives with an allotment of 100MB of storage. LabArchives is an Electronic 
Laboratory Notebook which will enable scientists to share and publish data files in
situ; you can then link your paper to these data. Data files linked to published articles 
are assigned digital object identifiers (DOIs) and will remain available in perpetuity. 
Use of LabArchives or similar data publishing services does not replace preexisting
data deposition requirements, such as for nucleic acid sequences, protein 
sequences and atomic coordinates.
Instructions on assigning DOIs to datasets, so they can be permanently linked to
publications, can be found on the LabArchives website. Use of LabArchives’ 
software has no influence on the editorial decision to accept or reject a manuscript.
Authors linking datasets to their publications should include an Availability of
supporting data section in their manuscript and cite the dataset in their reference list.
Preparing main manuscript text
General guidelines of the journal's style and language are given below.
Overview of manuscript sections for Research articles
Manuscripts for Research articles submitted to BMC Public Health should be divided






 Results and discussion
 Conclusions
















 Illustrations and figures (if any)
 Tables and captions
 Preparing additional files
The Accession Numbers of any nucleic acid sequences, protein sequences or 
atomic coordinates cited in the manuscript should be provided, in square brackets 
and include the corresponding database name; for example, [EMBL:AB026295, 
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-
Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide 
Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the 
NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and 
the Swiss-Prot Protein Database (Swiss-Prot). 
You can download a template (Mac and Windows compatible; Microsoft Word 
98/2000) for your article.
For reporting standards please see the information in the About section. 
Title page 
The title page should: 
 provide the title of the article
 list the full names, institutional addresses and email addresses for all authors
 indicate the corresponding author
Please note: 
 the title should includ the study design, for example "A versus B in the
treatment of C: a randomized controlled trial X is a risk factor for Y: a case
control study"
 abbreviations within the title should be avoided
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured 
into separate sections: Background, the context and purpose of the study; 
Methods, how the study was performed and statistical tests used; Results, the main 
findings; Conclusions, brief summary and potential implications. Please minimize 
the use of abbreviations and do not cite references in the abstract. Trial
registration, if your research article reports the results of a controlled health care 
intervention, please list your trial registry, along with the unique identifying number 
(e.g. Trial registration: Current Controlled Trials ISRCTN73824458). Please note 
that there should be no space between the letters and numbers of your trial 
registration number. We recommend manuscripts that report randomized controlled 











Three to ten keywords representing the main content of the article. 
Background 
The Background section should be written in a way that is accessible to researchers 
without specialist knowledge in that area and must clearly state - and, if helpful, 
illustrate - the background to the research and its aims. Reports of clinical research 
should, where appropriate, include a summary of a search of the literature to indicate 
why this study was necessary and what it aimed to contribute to the field. The 
section should end with a brief statement of what is being reported in the article. 
Methods 
The methods section should include the design of the study, the setting, the type of
participants or materials involved, a clear description of all interventions and
comparisons, and the type of analysis used, including a power calculation if
appropriate. Generic drug names should generally be used. When proprietary
brands are used in research, include the brand names in parentheses in the
Methods section.
For studies involving human participants a statement detailing ethical approval and
consent should be included in the methods section. For further details of the journal's 
editorial policies and ethical guidelines see 'About this journal'.
For further details of the journal's data-release policy, see the policy section in 'About
this journal'.
Results and discussion 
The Results and discussion may be combined into a single section or presented
separately. Results of statistical analysis should include, where appropriate, relative
and absolute risks or risk reductions, and confidence intervals. The Results and
discussion sections may also be broken into subsections with short, informative
headings.
Conclusions 
This should state clearly the main conclusions of the research and give a clear 
explanation of their importance and relevance. Summary illustrations may be 
included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, 
and a list of abbreviations can be provided, which should precede the competing 











A competing interest exists when your interpretation of data or presentation of 
information may be influenced by your personal or financial relationship with other 
people or organizations. Authors must disclose any financial competing interests; 
they should also reveal any non-financial competing interests that may cause them 
embarrassment were they to become public after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing 
interests that are declared will be listed at the end of published articles. Where an 
author gives no competing interests, the listing will read 'The author(s) declare that 
they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past five years have you received reimbursements, fees, funding, or 
salary from an organization that may in any way gain or lose financially from 
the publication of this manuscript, either now or in the future? Is such an 
organization financing this manuscript (including the article-processing 
charge)? If so, please specify. 
 Do you hold any stocks or shares in an organization that may in any way gain 
or lose financially from the publication of this manuscript, either now or in the 
future? If so, please specify. 
 Do you hold or are you currently applying for any patents relating to the 
content of the manuscript? Have you received reimbursements, fees, funding, 
or salary from an organization that holds or has applied for patents relating to 
the content of the manuscript? If so, please specify. 
 Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests  
Are there any non-financial competing interests (political, personal, religious, 
ideological, academic, intellectual, commercial or any other) to declare in relation to 
this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing 
interest please discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual 
contributions of authors to the manuscript should be specified in this section. 
An 'author' is generally considered to be someone who has made substantive 
intellectual contributions to a published study. To qualify as an author one should 1) 
have made substantial contributions to conception and design, or acquisition of data, 
or analysis and interpretation of data; 2) have been involved in drafting the 










final approval of the version to be published. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the 
content. Acquisition of funding, collection of data, or general supervision of the 
research group, alone, does not justify authorship.  
We suggest the following kind of format (please use initials to refer to each author's 
contribution): AB carried out the molecular genetic studies, participated in the 
sequence alignment and drafted the manuscript. JY carried out the immunoassays. 
MT participated in the sequence alignment. ES participated in the design of the study 
and performed the statistical analysis. FG conceived of the study, and participated in 
its design and coordination and helped to draft the manuscript. All authors read and 
approved the final manuscript.  
All contributors who do not meet the criteria for authorship should be listed in an
acknowledgements section. Examples of those who might be acknowledged include
a person who provided purely technical help, writing assistance, or a department
chair who provided only general support.
Authors' information 
You may choose to use this section to include any relevant information about the
author(s) that may aid the reader's interpretation of the article, and understand the
standpoint of the author(s). This may include details about the authors' qualifications, 
current positions they hold at institutions or societies, or any other relevant 
background information. Please refer to authors using their initials. Note this section
should not be used to describe any competing interests.
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manuscript preparation. Authors must describe the role of the funding body, if any, in 
design, in the collection, analysis, and interpretation of data; in the writing of the
manuscript; and in the decision to submit the manuscript for publication. Please also 
acknowledge anyone who contributed materials essential for the study. If a language
editor has made significant revision of the manuscript, we recommend that you
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The role of a scientific (medical) writer must be included in the acknowledgements 
section, including their source(s) of funding. We suggest wording such as 'We thank 
Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals 
Ltd.' 












Endnotes should be designated within the text using a superscript lowercase letter 
and all notes (along with their corresponding letter) should be included in the 
Endnotes section. Please format this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, 
in the order in which they are cited in the text, followed by any in tables or legends. 
Each reference must have an individual reference number. Please avoid excessive 
referencing. If automatic numbering systems are used, the reference numbers must 
be finalized and the bibliography must be fully formatted before submission. 
Only articles, datasets, clinical trial registration records and abstracts that have been 
published or are in press, or are available through public e-print/preprint servers, 
may be cited; unpublished abstracts, unpublished data and personal 
communications should not be included in the reference list, but may be included in 
the text and referred to as "unpublished observations" or "personal communications" 
giving the names of the involved researchers. Obtaining permission to quote 
personal communications and unpublished data from the cited colleagues is the 
responsibility of the author. Footnotes are not allowed, but endnotes are permitted. 
Journal abbreviations follow Index Medicus/MEDLINE. Citations in the reference list 
should include all named authors, up to the first 30 before adding 'et al.'.. 
Any in press articles cited within the references and necessary for the reviewers' 
assessment of the manuscript should be made available if requested by the editorial 
office. 
Style files are available for use with popular bibliographic management software: 
 BibTeX 
 EndNote style file 
 Reference Manager 
 Zotero 
Examples of the BMC Public Health reference style are shown below. Please ensure 
that the reference style is followed precisely; if the references are not in the correct 
style they may have to be retyped and carefully proofread.  
All web links and URLs, including links to the authors' own websites, should be given 
a reference number and included in the reference list rather than within the text of 
the manuscript. They should be provided in full, including both the title of the site and 
the URL, in the following format: The Mouse Tumor Biology Database 
[http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or group of authors can 
clearly be associated with a web link, such as for weblogs, then they should be 











Examples of the BMC Public Health reference style 
Article within a journal
Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat
Genet 1996, 13:266-267. 
Article within a journal supplement
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of
ab initio three-dimensional prediction, secondary structure, and contacts 
prediction. Proteins 1999, 43(Suppl 3):149-170. 
In press article
Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, 
in press. 
Published abstract
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal 
cells, stromal derived factor-1 and rheumatoid arthritis [abstract]. Arthritis 
Rheum 1999, 42:s250.
Article within conference proceedings
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National 
Conference on Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. 
Stoneham: Butterworth-Heinemann; 1996:16-27.
Book chapter, or article within a book
Schnepf E: From prey via endosymbiont to plastids: comparative studies in 
dinoflagellates. In Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA.
New York: Chapman and Hall; 1993:53-76.
Whole issue of journal
Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer 
Res 1998, 10:1-72.
Whole conference proceedings
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30
June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996. 
Complete book
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970. 
Monograph or book in a series
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells
and Tissues. Edited by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner 
G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.] 
Book with institutional author











Kohavi R: Wrappers for performance enhancement and oblivious decision 
graphs. PhD thesis. Stanford University, Computer Science Department; 1995. 
Link / URL 
The Mouse Tumor Biology Database 
[http://tumor.informatics.jax.org/mtbwi/index.do] 
Link / URL with author(s) 
Corpas M: The Crowdfunding Genome Project: a personal genomics 
community with open source values 
[http://blogs.biomedcentral.com/bmcblog/2012/07/16/the-crowdfunding-genome-
project-a-personal-genomics-community-with-open-source-values/]  
Dataset with persistent identifier 
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; 
Ramachandran, S; Liu, C-M; Jing, H-C (2011): Genome data from sweet and grain 
sorghum (Sorghum bicolor). GigaScience. http://dx.doi.org/10.5524/100012. 
Clinical trial registration record with persistent identifier 
Mendelow, AD (2006): Surgical Trial in Lobar Intracerebral Haemorrhage. 
Current Controlled Trials. http://dx.doi.org/10.1186/ISRCTN22153967 
Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each 
figure should include a single illustration and should fit on a single page in portrait 
format. If a figure consists of separate parts, it is important that a single composite 
illustration file be submitted which contains all parts of the figure. There is no charge 
for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising 
the quality of your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams) 
 DOCX/DOC (single page only) 
 PPTX/PPT (single slide only) 
 EPS 















The legends should be included in the main manuscript text file at the end of the 
document, rather than being a part of the figure file. For each figure, the following 
information should be provided: Figure number (in sequence, using Arabic numerals 
- i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up
to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission 
from the copyright holder to reproduce figures or tables that have previously 
been published elsewhere.
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. 
Table 1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes 
the whole table; it should be no longer than 15 words. Detailed legends may then
follow, but they should be concise. Tables should always be cited in text in 
consecutive numerical order.
Smaller tables considered to be integral to the manuscript can be pasted into the end
of the document text file, in A4 portrait or landscape format. These will be typeset 
and displayed in the final published form of the article. Such tables should be
formatted using the 'Table object' in a word processing program to ensure that 
columns of data are kept aligned when the file is sent electronically for review; this 
will not always be the case if columns are generated by simply using tabs to
separate text. Columns and rows of data should be made visibly distinct by ensuring
that the borders of each cell display as black lines. Commas should not be used to
indicate numerical values. Color and shading may not be used; parts of the table can
be highlighted using symbols or bold text, the meaning of which should be explained
in a table legend. Tables should not be embedded as figures or spreadsheet files.
Larger datasets or tables too wide for a portrait page can be uploaded separately as 
additional files. Additional files will not be displayed in the final, laid-out PDF of the 
article, but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet 
(.xls ) or comma separated values (.csv). As with all files, please use the standard 
file extensions. 
Preparing additional files 
Although BMC Public Health does not restrict the length and quantity of data 
included in an article, we encourage authors to provide datasets, tables, movies, or 










Please note: All Additional files will be published along with the article. Do not 
include files such as patient consent forms, certificates of language editing, or 
revised versions of the main manuscript document with tracked changes. Such files 
should be sent by email to editorial@biomedcentral.com, quoting the Manuscript ID 
number. 
Results that would otherwise be indicated as "data not shown" can and should be 
included as additional files. Since many weblinks and URLs rapidly become broken, 
BMC Public Health requires that supporting data are included as additional files, or 
deposited in a recognized repository. Please do not link to data on a 
personal/departmental website. The maximum file size for additional files is 20 MB 
each, and files will be virus-scanned on submission.  
Additional files can be in any format, and will be downloadable from the final 
published article as supplied by the author. We recommend CSV rather than PDF for 
tabular data.
Certain supported files formats are recognized and can be displayed to the user in
the browser. These include most movie formats (for users with the Quicktime plugin), 
mini-websites prepared according to our guidelines, chemical structure files (MOL, 
PDB), geographic data files (KML). 
If additional material is provided, please list the following information in a separate
section of the manuscript text:
 File name (e.g. Additional file 1)
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx
(including name and a URL of an appropriate viewer if format is unusual)
 Title of data
 Description of data
Additional files should be named "Additional file 1" and so on and should be
referenced explicitly by file name within the body of the article, e.g. 'An additional 
movie file shows this in more detail [see Additional file 1]'.
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be 
viewable using free or widely available tools. The following are examples of suitable 
formats. 
 Additional documentation
o PDF (Adode Acrobat)
 Animations
o SWF (Shockwave Flash)
 Movies
o MP4 (MPEG 4)
o MOV (Quicktime)
 Tabular data










o CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that 
they will be browsable from within the full text HTML version of the article. In order to 
do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in the 
root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-
folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than 
"/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or 
"C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure that 
the most commonly used browsers (Internet Explorer and Firefox) are able to 
view all parts of the mini-website without problems, it is ideal to check this on 
a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that 
index.html is in the root of the ZIP, and that the file has .zip extension, then 
submit as an additional file with your article. 
Style and language 
General 
Currently, BMC Public Health can only accept manuscripts written in English. 
Spelling should be US English or British English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are 
encouraged to be concise.  
BMC Public Health will not edit submitted manuscripts for style or language; 
reviewers may advise rejection of a manuscript if it is compromised by grammatical 
errors. Authors are advised to write clearly and simply, and to have their article 
checked by colleagues before submission. In-house copyediting will be minimal. 
Non-native speakers of English may choose to make use of a copyediting service. 
Language editing 
For authors who wish to have the language in their manuscript edited by a native-
English speaker with scientific expertise, BioMed Central recommends Edanz. 










authors by Edanz. Use of an editing service is neither a requirement nor a guarantee 
of acceptance for publication. Please contact Edanz directly to make arrangements 
for editing, and for pricing and payment details. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, 
please visit our page on Writing titles and abstracts for scientific articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific 
manuscript. American Scientist also provides a list of resources for science writing. 
For more detailed guidance on preparing a manuscript and writing in English, please 
visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined
when first used and a list of abbreviations can be provided following the main 
manuscript text.
Typography 
 Please use double line spacing.
 Type the text unjustified, without hyphenating words at line breaks.
 Use hard returns only to end headings and paragraphs, not to rearrange lines.
 Capitalize only the first word, and proper nouns, in the title.
 All pages should be numbered.
 Use the BMC Public Health reference format.
 Footnotes are not allowed, but endnotes are permitted.
 Please do not format the text in multiple columns.
 Greek and other special characters may be included. If you are unable to
reproduce a particular special character, please type out the name of the
symbol in full. Please ensure that all special characters used are
embedded in the text, otherwise they will be lost during conversion to 
PDF.
Units 
SI units should be used throughout (liter and molar are permitted, however). 
